Together, these results reveal a CeM-CRH<sup>PVH</sup>-hepatic sympathetic axis that couples central stress signaling to peripheral β-adrenergic desensitization and lipid dysregulation, thereby suggesting a potential therapeutic strategy for stress-related MASLD. Here, CRH is linked to metabolic dysfunction-associated steatotic liver disease.